Muscular effects of statins in the elderly female: a review

References

• National Center for Health StatisticsHealth, United States, 2010: With Special Feature on Death and DyingHyattsville (MD)National Center for Health Statistics2011
   Google Scholar
• BaigentCKeechAKearneyPMEfficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statinsLancet20053661267127816214597
   PubMed Web of Science ®Google Scholar
• WalshJMEPignoneMDrug treatment for hyperlipidemia in womenJAMA20042912243225215138247
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative GroupMRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trialLancet200236072212114036
   PubMed Web of Science ®Google Scholar
• LemaitreRNFurbergCDNewmanABTime trends in the use of cholesterol-lowering agents in older adults: the cardiovascular health studyArch Intern Med1998158176117689738605
   PubMed Web of Science ®Google Scholar
• RallidisLSFountoulakiKAnastasiou-NanaMManaging the underestimated risk of statin-associated myopathyInt J Cardiol201215916917621813193
   PubMed Web of Science ®Google Scholar
• BaysHStatin safety: an overview and assessment of the data - 2005Am J Cardiol2006976C26C
   PubMed Web of Science ®Google Scholar
• IMS Institute for Health InformaticsThe Use of Medicines in the United States: Review of 2011Parsippany, NJIMS Institute for Health Informatics2012 Available from: http://www.imshealth.com/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/IHII_Medicines_in_U.S_Report_2011.pdfAccessed October 15,2012
   Google Scholar
• PasternakRCSmithSC JrBairey-MerzCNACC/AHA/NHLBI clinical advisory on the use and safety of statinsCirculation20021061024102812186811
   PubMed Web of Science ®Google Scholar
• McKenneyJMDavidsonMHJacobsonTAGuytonJRNational Lipid Association Statin Safety Assessment Task ForceFinal conclusions and recommendations of the national lipid association statin safety assessment task forceAm J Cardiol20069789C94C
   PubMed Web of Science ®Google Scholar
• SathasivamSStatin induced myotoxicityEur J Intern Med20122331732422560377
   PubMed Web of Science ®Google Scholar
• AlexanderKPBlazingMARosensonRSManagement of hyperlipidemia in older adultsJ Cardiovasc Pharmacol Ther200914495819124599
   PubMed Web of Science ®Google Scholar
• GaistDRodríguezLAHuertaCHallasJSindrupSHLipid-lowering drugs and risk of myopathy: a population-based follow-up studyEpidemiology20011256556911505177
   PubMed Web of Science ®Google Scholar
• JoyTRHegeleRANarrative review: statin-related myopathyAnn Intern Med200915085886819528564
   PubMed Web of Science ®Google Scholar
• LaRosaJCGrundySMWatersDDIntensive lipid lowering with atorvastatin in patients with stable coronary diseaseN Engl J Med200573521425143515755765
   PubMed Web of Science ®Google Scholar
• ThompsonPDClarksonPKarasRHStatin-associated myopathyJAMA20032891681169012672737
   PubMed Web of Science ®Google Scholar
• NicholsGAKoroCEDoes statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patientsClin Ther2007291761177017919557
   PubMed Web of Science ®Google Scholar
• BruckertEHayemGDejagerSYauCBégaudBMild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO studyCardiovasc Drugs Ther20051940341416453090
   PubMed Web of Science ®Google Scholar
• NewmanCBSzarekMColhounHMThe safety and tolerability of atorvastatin 10 mg in the collaborative atorvastatin diabetes study (CARDS)Diab Vasc Dis Res2008517718318777490
   PubMed Web of Science ®Google Scholar
• BallantyneCMCorsiniADavidsonMHRisk for myopathy with statin therapy in high-risk patientsArch Intern Med200316355356412622602
   PubMed Web of Science ®Google Scholar
• EvansMReesAEffects of HMG-CoA reductase inhibitors on skeletal muscle: Are all statins the same?Drug Saf20022564966312137559
   PubMed Web of Science ®Google Scholar
• MillsEJWuPChongGEfficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trialsQJM201110410912420934984
   PubMed Web of Science ®Google Scholar
• InsullWJrIsaacsohnJKwiterovichPEfficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study GroupJ Int Med Res200828476810898118
   PubMed Web of Science ®Google Scholar
• JacobsonTAStatin safety: lessons from new drug applications for marketed statinsAm J Cardiol20069744C51C16377282
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and ResearchBaycol medical review1999 Available from http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-740S008_Baycol_medr.pdfAccessed October 10, 2012
   Google Scholar
• BoetjeMBunoutDBarreraGde la MazaMPLeivaLHirschSEffects of statin use on functional capacity and muscle mass in elderly womenAgeing Res201123539
   Google Scholar
• KostisWJChengJQDobrzynskiJMCabreraJKostisJBMetaanalysis of statin effects in women versus menJ Am Coll Cardiol20125957258222300691
   PubMed Web of Science ®Google Scholar
• KunclRWAgents and mechanisms of toxic myopathyCurr Opin Neurol20092250651519680127
   PubMed Web of Science ®Google Scholar
• VaklavasCChatzizisisYSZiakasAZamboulisCGiannoglouGDMolecular basis of statin-associated myopathyAtherosclerosis2009202182818585718
   PubMed Web of Science ®Google Scholar
• NishimotoTTozawaRAmanoYWadaTImuraYSugiyamaYComparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytesBiochem Pharmacol2003662133213914609738
   PubMed Web of Science ®Google Scholar
• MatznoSYamauchiTGohdaMInhibition of cholesterol biosynthesis by squalene epoxidase inhibitor avoids apoptotic cell death in L6 myoblastsJ Lipid Res199738163916489300786
   PubMed Web of Science ®Google Scholar
• MarcoffLThompsonPDThe role of coenzyme Q10 in statin-associated myopathy: a systematic reviewJ Am Coll Cardiol2007492231223717560286
   PubMed Web of Science ®Google Scholar
• BeltowskiJWôjcickaGJamroz-WisniewskaAAdverse effects of statins - mechanisms and consequencesCurr Drug Saf2009420922819534648
   PubMedGoogle Scholar
• ChatzizisisYSVaklavasCGiannoglouGDCoenzyme Q10 depletion: Etiopathogenic or predisposing factor in statin associated myopathy?Am J Cardiol2008101107118359340
   PubMed Web of Science ®Google Scholar
• BakerSKMolecular clues into the pathogenesis of statin-mediated muscle toxicityMuscle Nerve20053157258015712281
   PubMed Web of Science ®Google Scholar
• GuijarroCBlanco-ColioLMOrtegoM3-hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in cultureCirc Res1998834905009734471
   PubMed Web of Science ®Google Scholar
• GhatakAFaheemOThompsonPDThe genetics of statin-induced myopathyAtherosclerosis201021033734320042189
   PubMed Web of Science ®Google Scholar
• MangoniAAJacksonSHAge-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applicationsBr J Clin Pharmacol20045761414678335
   PubMed Web of Science ®Google Scholar
• ElDesokyESPharmacokinetic-pharmacodynamic crisis in the elderlyAm J Ther20071448849817890940
   PubMedGoogle Scholar
• ParkerBAThompsonPDEffect of statins on skeletal muscle: exercise, myopathy, and muscle outcomesExerc Sport Sci Rev20124018819423000957
   PubMed Web of Science ®Google Scholar
• SzadkowskaIStanczykAAronowWSStatin therapy in the elderly: a reviewArch Gerontol Geriatr20105011411819217673
   PubMed Web of Science ®Google Scholar
• AndersonGDGender differences in pharmacological responseInt Rev Neurobiol20088311018929073
   PubMed Web of Science ®Google Scholar
• Hofer-DueckelmannCPrinzEBeindlWAdverse drug reactions (ADRs) associated with hospital admissions - elderly female patients are at highest riskInt J Clin Pharmacol Ther20114957758621961482
   PubMed Web of Science ®Google Scholar
• FattingerKRoosMVergèresPEpidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicineBr J Clin Pharmacol20004915816710671911
   PubMed Web of Science ®Google Scholar
• TranCKnowlesSRLiuBAShearNHGender differences in adverse drug reactionsJ Clin Pharmacol199838100310099824780
   PubMed Web of Science ®Google Scholar
• CicconeGKHoldcroftADrugs and sex differences: a review of drugs relating to anaesthesiaBr J Anaesth19998225526510365004
   PubMed Web of Science ®Google Scholar
• SicaDAGehrTWBRhabdomyolysis and statin therapy: relevance to the elderlyAm J Geriatr Cardiol200211485511773716
   PubMedGoogle Scholar
• WolboldRKleinKBurkOSex is a major determinant of CYP3A4 expression in human liverHepatology20033897898814512885
   PubMed Web of Science ®Google Scholar
• GruerPJVegaJMMercuriMFDobrinskaMRTobertJAConcomitant use of cytochrome P450 3A4 inhibitors and simvastatinAm J Cardiol19998481181510513779
   PubMed Web of Science ®Google Scholar
• YoshidaMMatsumotoTSuzukiTKitamuraSMayamaTEffect of concomitant treatment with a CYP3A4 inhibitor and a calcium channel blockerPharmacoepidemiol Drug Saf200817707517918187
   PubMed Web of Science ®Google Scholar
• KaikkonenJNyyssönenKTuomainenTPRistonmaaUSalonenJTDeterminants of plasma coenzyme Q10 in humansFEB S Lett1999443163166
   PubMed Web of Science ®Google Scholar
• RacineMTousignant-LaflammeYKlodaLADionDDupuisGChoinièreMA systematic literature review of 10 years of research on sex/gender and pain perception - part 2: do biopsychosocial factors alter pain sensitivity differently in women and men? Pain201215361963522236999
   PubMed Web of Science ®Google Scholar
• GoffauxPMichaudKGaudreauJChalayePRainvillePMarchandSSex differences in perceived pain are affected by an anxious brainPain20111522065207321665365
   PubMed Web of Science ®Google Scholar
• VladutiuGDSimmonsZIsacksonPJGenetic risk factors associated with lipid-lowering drug-induced myopathiesMuscle Nerve20063415316216671104
   PubMed Web of Science ®Google Scholar
• LinkEParishSArmitageJSLC01B1 variants and statin-induced myopathy - a genome-wide studyN Engl J Med200835978979918650507
   PubMed Web of Science ®Google Scholar
• WilkeRARamseyLBJohnsonSGThe clinical pharmacogenomics implementation consortium: CPIC guideline for SLCOIBI and simvastatin-induced myopathyClin Pharmacol Ther20129211211722617227
   PubMed Web of Science ®Google Scholar
• PasanenMKFredriksonHNeuvonenPJNiemiMDifferent effects of SLCOIBI polymorphism on the pharmacokinetics of atorvastatin and rosuvastatinClin Pharmacol Ther20078272673317473846
   PubMed Web of Science ®Google Scholar
• BrunhamLRLansbergPJZhangLDifferential effect of the rs4149056 variant in SLCOIBI on myopathy associated with simvastatin and atorvastatinPharmacogenomics J20121223323721243006
   PubMed Web of Science ®Google Scholar
• SantosPCSoaresRANascimentoRMSLCOIBI rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic groupBMC Med Genet20111213621992719
   PubMed Web of Science ®Google Scholar
• RuanoGWindemuthAWuAHMechanisms of statin-induced myalgia assessed by physiogenomic associationsAtherosclerosis201121845145621868014
   PubMed Web of Science ®Google Scholar
• WilkeRAMooreJHBurmesterJKRelative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damagePharmacogenet Genomics20051541542115900215
   PubMed Web of Science ®Google Scholar
• ThompsonPDClarksonPMRosensonRSNational Lipid Association Statin Safety Task Force Muscle Safety Expert PanelAn assessment of statin safety by muscle expertsAm J Cardiol20069769C76C
   PubMed Web of Science ®Google Scholar
• BlomDJStatin therapy for the octogenarian? J Endocrinol Metab Diabetes South Afr2012173742
   Google Scholar
• BresslerRBahlJJPrinciples of drug therapy for the elderly patientMayo Clin Proc2003781564157714661688
   PubMed Web of Science ®Google Scholar
• AroraRLieboMMaldonadoFStatin-induced myopathy: the two faces of JanusJ Cardiovasc Pharmacol Ther20061110511216891287
   PubMed Web of Science ®Google Scholar
• SchneckDWBirminghamBKZalikowskiJAThe effect of gemfibrozil on the pharmakonietics of rosuvastatinClin Pharmacol Ther20047545546315116058
   PubMed Web of Science ®Google Scholar
• CorsiniACeskaRDrug-drug interactions with statins: will pravastatin overcome the statins’ Achilles heel?Curr Med Res Opin2011271551156221682551
   PubMed Web of Science ®Google Scholar
• JonesPDavidsonMReporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statinAm J Cardiol20069512012215619408
   PubMed Web of Science ®Google Scholar
• NeuvonenPJNiemiMBackmanJTDrug interactions with lipid lowering drugs: mechanisms and clinical relevanceClin Pharmacol Ther20068056558117178259
   PubMed Web of Science ®Google Scholar
• ParkerBAAugeriALCapizziJAEffect of statins on creatine kinase levels before and after a marathon runAm J Cardiol201210928228722036108
   PubMed Web of Science ®Google Scholar
• HansenKEHildebrandJPFergusonEESteinJHOutcomes in 45 patients with statin-associated myopathyArch Intern Med20051652671267616344427
   PubMed Web of Science ®Google Scholar
• FrancSDejagerSBruckertEChauvenetMGiralPTurpinGA comprehensive description of muscle symptoms associated with lipid-lowering drugsCardiovasc Drugs Ther20031745946515107601
   PubMed Web of Science ®Google Scholar
• MascitelliLPezzettaFDoes statin therapy interfere with the ability of claudicant patients to exercise?Vasc Endovascular Surg20074147317942867
   PubMedGoogle Scholar
• MarooBPLavieCJMilaniRVEfficacy and safety of intensive statin therapy in the elderlyAm J Geriatr Cardiol2008179210018326948
   PubMedGoogle Scholar
• KulikARuelMStatins and coronary artery bypass graft surgery: preoperative and postoperatice efficacy and safetyExpert Opin Drug Saf2009855957119673591
   PubMed Web of Science ®Google Scholar
• DesaiHAronowWSAhnCIncidence of perioperative myocardial infarction and of 2-year mortality in 577 elderly patients undergoing noncardiac vascular surgery treated with and without statinsArch Gerontol Geriatr20105114915119819571
   PubMed Web of Science ®Google Scholar
• JickHZornbergGLJickSSSeshadriSDrachmanDAStatins and the risk of dementiaLancet20003561627163111089820
   PubMed Web of Science ®Google Scholar
• 78FreemanDJNorrieJSattarNPravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention StudyCirculation200110335736211136689
   PubMed Web of Science ®Google Scholar
• SpósitoACMansurAPCoelhoORNicolauJCRamiresJAAdditional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril)Am J Cardiol1999831497149910335771
   PubMed Web of Science ®Google Scholar
• LeungBPSattarNCrillyAA novel anti-inflammatory role for simvastatin in inflammatory arthritisJ Immunol20031701524153012538717
   PubMed Web of Science ®Google Scholar
• LemoineSAlloucheSCoulbaultLMechanisms involved in cardioprotective effects of pravastatin administered during reoxygenation in human myocardium in vitroAnesthesiology201211682483322343498
   PubMed Web of Science ®Google Scholar
• OsmakMStatins and cancer: current and future prospectsCancer Lett201232411222542807
   PubMed Web of Science ®Google Scholar
• LutskiMShalevVPorathAChodickGContinuation with statin therapy and the risk of primary cancer: a population-based studyPrev Chronic Dis20129E131
   Google Scholar
• SchneiderEBEfronDTMacKenzieEJRivaraFPNathensABJurkovichGJPremorbid statin use is associated with improved survival and functional outcomes in older head-injured individualsJ Trauma20117181581921986733
   PubMedGoogle Scholar
• MarooBPLavieCJMilaniRVSecondary prevention of coronary heart disease in elderly patients following myocardial infarction: are all HMG-CoA reductase inhibitors alike? Drugs Aging20082564966418665658
   PubMed Web of Science ®Google Scholar
• KoDTMamdaniMAlterDALipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradoxJAMA20042911864187015100205
   PubMed Web of Science ®Google Scholar
• SirventPMercierJLacampagneANew insights into mechanisms of statin-associated myotoxicityCurr Opin Pharmacol2008833333818243052
   PubMed Web of Science ®Google Scholar